TY - JOUR
T1 - Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2
T2 - Implications for vaccine dose interval
AU - Miyamoto, Sho
AU - Kuroda, Yudai
AU - Kanno, Takayuki
AU - Ueno, Akira
AU - Shiwa-Sudo, Nozomi
AU - Iwata-Yoshikawa, Naoko
AU - Sakai, Yusuke
AU - Nagata, Noriyo
AU - Arashiro, Takeshi
AU - Ainai, Akira
AU - Moriyama, Saya
AU - Kishida, Noriko
AU - Watanabe, Shinji
AU - Nojima, Kiyoko
AU - Seki, Yohei
AU - Mizukami, Takuo
AU - Hasegawa, Hideki
AU - Ebihara, Hideki
AU - Fukushi, Shuetsu
AU - Takahashi, Yoshimasa
AU - Maeda, Ken
AU - Suzuki, Tadaki
N1 - Funding Information:
We thank Akiko Sataka, Asato Kojima, Izumi Kobayashi, Yuki Iwamoto, Yuko Sato, Milagros Virhuez Mendoza, Noriko Nakajima, Kenta Takahashi, and Emi Taeda at NIID for their technical support; Jumpei Ito at the University of Tokyo for technical advice on Bayesian modeling; and the healthcare facilities, local health centers, and public health institutes for their contribution in providing us with patient information and samples on pre-Omicron breakthrough cases as listed previously.9 We also thank the Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture governments for their support in implementing the study; staff members at the Survey Research Center and Mitsubishi Research Institute for their administrative and technical assistance; and GISAID for the platform to share and compare our data with data submitted globally. This work was supported by a Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) grant 21K20768 (to S.Mi.), by Ministry of Health, Labour and Welfare (MHLW) grants 20HA2001 (to T.S.), and 21HA2005 (to T.S.), and by Japan Agency for Medical Research and Development (AMED) grants JP21fk0108104 (to T.S.), JP22fk0108637 (to T.S.), JP22fk0108141(to T.S.) and JP22fk0108509 (to T.S.). Conceptualization, S.Mi. Y.K. K.M. T.S.; Methodology, S.Mi. T.A. A.U. T.K. K.M. T.S.; Investigation, S.Mi. Y.K. T.K. A.U. N.S. N.I. Y.S. N.N. T.A. A.A. S.Mo. N.K. S.W. K.N. Y.S. T.M. H.H. H.E. S.F. Y.T. K.M. T.S.; Data curation, S.Mi. Y.K. T.K. T.A. S.Mo. S.F. S.W. T.M. T.S.; Formal analysis and Visualization, S.Mi. T.S.; Funding acquisition, S.Mi. T.S.; Project administration and supervision, H.H. H.E. S.F. Y.T. K.M. T.S.; Writing original draft, S.Mi,. T.S.; Writing – review & editing, S.Mi. Y.K. A.U. K.M. T.S. All authors agreed to submit the manuscript, read and approved the final draft, and take full responsibility of its content including the accuracy of the data and statistical analysis. The authors declare no competing interests.
Funding Information:
We thank Akiko Sataka, Asato Kojima, Izumi Kobayashi, Yuki Iwamoto, Yuko Sato, Milagros Virhuez Mendoza, Noriko Nakajima, Kenta Takahashi, and Emi Taeda at NIID for their technical support; Jumpei Ito at the University of Tokyo for technical advice on Bayesian modeling; and the healthcare facilities, local health centers, and public health institutes for their contribution in providing us with patient information and samples on pre-Omicron breakthrough cases as listed previously. 9 We also thank the Miyagi, Tokyo, Aichi, Osaka, and Fukuoka prefecture governments for their support in implementing the study; staff members at the Survey Research Center and Mitsubishi Research Institute for their administrative and technical assistance; and GISAID for the platform to share and compare our data with data submitted globally. This work was supported by a Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) grant 21K20768 (to S.Mi.), by Ministry of Health, Labour and Welfare (MHLW) grants 20HA2001 (to T.S.), and 21HA2005 (to T.S.), and by Japan Agency for Medical Research and Development (AMED) grants JP21fk0108104 (to T.S.), JP22fk0108637 (to T.S.), JP22fk0108141 (to T.S.) and JP22fk0108509 (to T.S.).
Publisher Copyright:
© 2023 The Authors
PY - 2023/5/19
Y1 - 2023/5/19
N2 - Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infection, is challenging. To compare the impact of pre-Omicron to Omicron breakthrough infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2–4 months. The breadths of saturated cross-neutralization responses to Omicron lineages were comparable in pre-Omicron and Omicron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages.
AB - Evaluating the serum cross-neutralization responses after breakthrough infection with various SARS-CoV-2 variants provides valuable insight for developing variant-proof COVID-19 booster vaccines. However, fairly comparing the impact of breakthrough infections with distinct epidemic timing on cross-neutralization responses, influenced by the exposure interval between vaccination and infection, is challenging. To compare the impact of pre-Omicron to Omicron breakthrough infection, we estimated the effects on cross-neutralizing responses by the exposure interval using Bayesian hierarchical modeling. The saturation time required to generate saturated cross-neutralization responses differed by variant, with variants more antigenically distant from the ancestral strain requiring longer intervals of 2–4 months. The breadths of saturated cross-neutralization responses to Omicron lineages were comparable in pre-Omicron and Omicron breakthrough infections. Our results highlight the importance of vaccine dosage intervals of 4 months or longer, regardless of the antigenicity of the exposed antigen, to maximize the breadth of serum cross-neutralization covering SARS-CoV-2 Omicron lineages.
KW - Immune response
KW - Immune system
KW - Immunity
KW - Virology
UR - http://www.scopus.com/inward/record.url?scp=85153801674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153801674&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2023.106694
DO - 10.1016/j.isci.2023.106694
M3 - Article
AN - SCOPUS:85153801674
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 5
M1 - 106694
ER -